This document is an excerpt from the EUR-Lex website
Document 62026CN0262
Case C-262/26, Genmab: Request for a preliminary ruling from the Sø- og Handelsretten (Denmark) lodged on 30 March 2026 – Genmab A/S v Ankenævnet for Patenter og Varemærker
Case C-262/26, Genmab: Request for a preliminary ruling from the Sø- og Handelsretten (Denmark) lodged on 30 March 2026 – Genmab A/S v Ankenævnet for Patenter og Varemærker
Case C-262/26, Genmab: Request for a preliminary ruling from the Sø- og Handelsretten (Denmark) lodged on 30 March 2026 – Genmab A/S v Ankenævnet for Patenter og Varemærker
OJ C, C/2026/2881, 8.6.2026, ELI: http://data.europa.eu/eli/C/2026/2881/oj (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
Official Journal |
EN C series |
|
C/2026/2881 |
8.6.2026 |
Request for a preliminary ruling from the Sø- og Handelsretten (Denmark) lodged on 30 March 2026 – Genmab A/S v Ankenævnet for Patenter og Varemærker
(Case C-262/26, Genmab)
(C/2026/2881)
Language of the case: Danish
Referring court
Sø- og Handelsretten
Parties to the main proceedings
Applicant: Genmab A/S
Defendant: Ankenævnet for Patenter og Varemærker (Danish Board of Appeal for Patents and Trade Marks)
Questions referred
|
1. |
Must Article 1(b) and [Article] 3(b) of Regulation (EC) No 469/2009 (1) of the European Parliament and of the Council of 6 May 2009 be interpreted as meaning that a supplementary protection certificate can be granted for a product consisting of a new combination of active ingredients which has been granted a marketing authorisation in combination, notwithstanding the fact that the combination of active ingredients is not contained in the same physical pharmaceutical form, but instead constitutes a loose combination of active ingredients to be administered separately? |
|
2. |
If the answer to the first question is in the affirmative, can a variation of type II, within the meaning of Commission Regulation (EC) No 1234/2008 (2) of 24 November 2008, to a marketing authorisation pursuant to Directive 2001/83/ EC of a new combination of active ingredients which are not contained in the same physical pharmaceutical form, but instead constitute a loose combination of active ingredients to be administered separately, satisfy the condition laid down in Article 3(b)? |
(1) Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (OJ 2009 L 152, p. 1).
(2) Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products (OJ 2008 L 334, p. 7).
ELI: http://data.europa.eu/eli/C/2026/2881/oj
ISSN 1977-091X (electronic edition)